Categories
Jump to navigation
Jump to search
The following categories exist on the wiki, and may or may not be unused. Also see wanted categories.
(first | last) View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- Health Canada approved in 2014 (4 members)
- Health Canada approved in 2015 (5 members)
- Health Canada approved in 2016 (11 members)
- Health Canada approved in 2017 (6 members)
- Health Canada approved in 2018 (10 members)
- Health Canada approved in 2019 (13 members)
- Health Canada approved in 2020 (6 members)
- Health Canada approved in 2021 (15 members)
- Health Canada approved in 2022 (5 members)
- Health Canada approved in 2023 (2 members)
- Health Canada withdrawn in 2020 (1 member)
- Hedgehog pathway inhibitors (4 members)
- Hematologic bispecific antibodies (1 member)
- Hematologic monoclonal antibodies (6 members)
- Hematology & Oncology fellowship programs (25 members)
- Hematology & Oncology procedures (1 member)
- Hematology fellowship programs (0 members)
- Hematology medications (42 members)
- Hematology reference pages (12 members)
- Hematopoietic growth factors (12 members)
- Hemoglobin S polymerization inhibitors (1 member)
- Hemoglobinopathies (2 members)
- Hemolytic process (11 members)
- Hemophagocytic lymphohistiocytosis medications (7 members)
- Hemophagocytic lymphohistiocytosis regimens (1 member)
- Hemostasis medications (16 members)
- Heparin-induced thrombocytopenia medications (4 members)
- Heparin-induced thrombocytopenia medications (historic) (2 members)
- Heparin-induced thrombocytopenia regimens (1 member)
- Heparin antagonist (1 member)
- Heparins (7 members)
- Hepatic veno-occlusive disease medications (1 member)
- Hepatic veno-occlusive disease regimens (2 members)
- Hepatobiliary cancer medications (0 members)
- Hepatobiliary cancers (4 members)
- Hepatoblastoma medications (6 members)
- Hepatoblastoma regimens (1 member)
- Hepatocellular carcinoma medications (36 members)
- Hepatocellular carcinoma medications (historic) (2 members)
- Hepatocellular carcinoma regimens (3 members)
- Hepatopancreaticobiliary cancer regimens (7 members)
- Hereditary hemorrhagic telangiectasia medications (2 members)
- Hereditary hemorrhagic telangiectasia regimens (2 members)
- High-grade B-cell lymphoma medications (9 members)
- High-grade B-cell lymphoma regimens (1 member)
- High-grade glioma, pediatric medications (2 members)
- High-grade glioma, pediatric medications (investigational) (1 member)
- High-grade glioma medications (4 members)
- High-grade glioma regimens (3 members)
- High-grade gliomas (5 members)